Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 1, 2013, Pages 56-66

  Williams, Bryan ^a   Baschiera, Fabio ^b   Lacy, Peter S ^a   Botha, Jaco ^b   Prescott, Margaret F ^b   Brunel, Patrick ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; antihypertensive therapy; exercise testing; hypertension; plasma renin activity; treatment withdrawal; valsartan

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; N(G),N(G) DIMETHYLARGININE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BRONCHITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREADMILL EXERCISE;

ADULT; AGED; AMIDES; ARGININE; BLOOD PRESSURE; DEMOGRAPHY; ENDPOINT DETERMINATION; EXERCISE; FEMALE; FUMARATES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; TETRAZOLES; VALINE;

EID: 84874060177     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312454766     Document Type: Article

References (34)

1. Franz IW. Exercise hypertension: its measurement and evaluation. Herz. 1987 ; 12: 99-109
2. Moller NC, Grontved A, Wedderkopp N, et al. Cardiovascular disease risk factors and blood pressure response during exercise in healthy children and adolescents: the European Youth Heart Study. J Appl Physiol. 2010 ; 109: 1125-1132
3. Singh JP, Larson MG, Manolio TA, et al. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Circulation. 1999 ; 99: 1831-1836
4. Tanji JL, Champlin JJ, Wong GY, et al. Blood pressure recovery curves after submaximal exercise. A predictor of hypertension at ten-year follow-up. Am J Hypertens. 1989 ; 2: 135-138
5. Kurl S, Laukkanen JA, Rauramaa R, et al. Systolic blood pressure response to exercise stress test and risk of stroke. Stroke. 2001 ; 32: 2036-2041
6. Mundal R, Kjeldsen SE, Sandvik L, et al. Exercise blood pressure predicts mortality from myocardial infarction. Hypertension. 1996 ; 27: 324-329
7. Ren JF, Hakki AH, Kotler MN, et al. Exercise systolic blood pressure: a powerful determinant of increased left ventricular mass in patients with hypertension. J Am Coll Cardiol. 1985 ; 5: 1224-1231
8. Aldigier JC, Huang H, Dalmay F, et al. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993 ; 21: 289-295
9. Fallo F. Renin-angiotensin-aldosterone system and physical exercise. J Sports Med Phys Fitness. 1993 ; 33: 306-312
10. Warner JG, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999 ; 33: 1567-1572
11. Sullivan PA, Cervenka J, O'Connor DT, et al. Fosenopril, an angiotensin-converting enzyme inhibitor, and propranolol: comparative effects at rest and exercise on blood pressure, hormonal variables, and plasma potassium in essential hypertension. Cardiovasc Drugs Ther. 1989 ; 3: 57-62
12. Rangemark C, Lind H, Lindholm L, et al. Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension. Eur J Clin Pharmacol. 1996 ; 49: 267-271
13. Little WC, Wesley-Farrington DJ, Hoyle J, et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol. 2004 ; 43: 288-293
14. Duprez DA, Florea ND, Jones K, et al. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol. 2007 ; 50: 835-839
15. Czendlik CH, Sioufi A, Preiswerk G, et al. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur J Clin Pharmacol. 1997 ; 52: 451-459
16. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens. 2006 ; 24: 243-256
17. Prescott M, Wright M, Keefe D. Aliskiren, both as monotherapy and in combination with valsartan, reduces plasma aldosterone in patients with hypertension. J Hypertens. 2010 ; 28: e383
18. Fisher NDL, Danser AHJ, Nussberger J, et al. Renal and hormaonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008 ; 117: 3199-3205
19. Stevanovic RD, Price DA, Lansang MC, et al. Renin release in response to renin system blockade: Activation of the renin system in type 1 diabetes mellitus. JRAAS. 2005 ; 6: 78-83
20. Gibbons RJ, Balady GJ, Bricker JT, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002 ; 106: 1883-1892
21. Guidelines for cardiac exercise testing. Eur Heart J. 1993 ; 14: 969-988
22. Palatini P, Jung W, Shlyakhto E, et al. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens. 2010 ; 24: 93-103
23. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008 ; 51: 519-528
24. Ahlborg G, Lundberg JM. Exercise-induced changes in neuropeptide Y, noradrenaline and endothelin-1 levels in young people with type I diabetes. Clin Physiol. 1996 ; 16: 645-655
25. Lim PO, Donnan PT, MacDonald TM. Aldosterone to renin ratio as a determinant of exercise blood pressure response in hypertensive patients. J Hum Hypertens. 2001 ; 15: 119-123
26. Shim CY, Ha JW, Park S, et al. Exaggerated blood pressure response to exercise is associated with augmented rise of angiotensin II during exercise. J Am Coll Cardiol. 2008 ; 52: 287-292
27. Sullivan PA, Dineen M, Cervenka J, et al. Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension. Am J Hypertens. 1988 ; 1: 280S - 283S
28. Bair T, May H, Prescott M, et al. Association between baseline plasma renin activity and risk of cardiovascular events in coronary artery disease patients. J Clin Hypertens (Greenwich). 2009 ; 11: A88
29. Masson S, Solomon S, Angelici L, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2010 ; 16: 964-970
30. Muhlestein JB, May HT, Bair TL, et al. Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol. 2010 ; 106: 764-769
31. Vergaro G, Fontana M, Poletti R, et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur Heart J. 2008 ; 29: 393
32. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J. 2011 ; 32: 2135-2142
33. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011 ; 13: 100-106
34. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011 ; 13: 107-114